Research models to study lewy body dementia

被引：0
作者：
Suelen Lucio Boschen [1 ]
Aarushi A. Mukerjee [2 ]
Ayman H. Faroqi [1 ]
Ben E. Rabichow [3 ]
John Fryer [3 ]
机构：
[1] Department of Neuroscience, Mayo Clinic Jacksonville, 4500 San Pablo Rd, Jacksonville, 32224, FL
[2] Department of Neurosurgery, Mayo Clinic Jacksonville, 4500 San Pablo Rd, Jacksonville, 32224, FL
[3] Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, 200 First St. SW, Rochester, 55905, MN
[4] Translational Genomics Research Institute, 445 N 5th St, Phoenix, 850054, AZ
来源：
Molecular Neurodegeneration | / 20卷 / 1期
基金：
美国国家卫生研究院;
关键词：
Alpha-synuclein; Animal model; Beta-amyloid; Cell culture; Dementia with lewy body; Parkinson’s disease dementia; Synucleinopathy; Tau;
D O I：
10.1186/s13024-025-00837-w
中图分类号：
学科分类号：
摘要：
Lewy body dementia (LBD) encompasses neurodegenerative dementias characterized by cognitive fluctuations, visual hallucinations, and parkinsonism. Clinical differentiation of LBD from Alzheimer’s disease (AD) remains complex due to symptom overlap, yet approximately 25% of dementia cases are diagnosed as LBD postmortem, primarily identified by the presence of α-synuclein aggregates, tau tangles, and amyloid plaques. These pathological features position LBD as a comorbid condition of both Parkinson’s disease (PD) and AD, with over 50% of LBD cases exhibiting co-pathologies. LBD’s mixed pathology complicates the development of comprehensive models that reflect the full spectrum of LBD’s etiological, clinical, and pathological features. While existing animal and cellular models have facilitated significant discoveries in PD and AD research, they lack specificity in capturing LBD’s unique pathogenic mechanisms, limiting the exploration of therapeutic avenues for LBD specifically. This review assesses widely used PD and AD models in terms of their relevance to LBD, particularly focusing on their ability to replicate human disease pathology and assess treatment efficacy. Furthermore, we discuss potential modifications to these models to advance the understanding of LBD mechanisms and propose innovative research directions aimed at developing models with enhanced etiological, face, predictive, and construct validity. © The Author(s) 2025.
引用
收藏
相关论文
共 162 条
  • [91] McLean P., Kawamata H., Hyman B., α-Synuclein–enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons, Neuroscience, 104, 3, pp. 901-912, (2001)
  • [92] Outeiro T.F., Putcha P., Tetzlaff J.E., Spoelgen R., Koker M., Carvalho F., Et al., Formation of toxic oligomeric α-synuclein species in living cells, PLoS ONE, 3, 4, (2008)
  • [93] Lazaro D.F., Rodrigues E.F., Langohr R., Shahpasandzadeh H., Ribeiro T., Guerreiro P., Et al., Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation, PLoS Genet, 10, 11, (2014)
  • [94] Opazo F., Krenz A., Heermann S., Schulz J.B., Falkenburger B.H., Accumulation and clearance of α-synuclein aggregates demonstrated by time‐lapse imaging, J Neurochem, 106, 2, pp. 529-540, (2008)
  • [95] Klucken J., Outeiro T.F., Nguyen P., McLean P.J., Hyman B.T., Detection of novel intracellular O-synuclein oligomeric species by fluorescence lifetime imaging, FASEB J, 20, 12, pp. 2050-2057, (2006)
  • [96] Prusiner S.B., Woerman A.L., Mordes D.A., Watts J.C., Rampersaud R., Berry D.B., Et al., Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism, Proc Natl Acad Sci, 112, 38, pp. E5308-E5317, (2015)
  • [97] Delenclos M., Burgess J.D., Lamprokostopoulou A., Outeiro T.F., Vekrellis K., McLean P.J., Cellular models of alpha-synuclein toxicity and aggregation, J Neurochem, 150, 5, pp. 566-576, (2019)
  • [98] Fairfoul G., McGuire L.I., Pal S., Ironside J.W., Neumann J., Christie S., Et al., Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies, Ann Clin Transl Neurol, 3, 10, pp. 812-818, (2016)
  • [99] Iranzo A., Fairfoul G., Ayudhaya A.C.N., Serradell M., Gelpi E., Vilaseca I., Et al., Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study, Lancet Neurol, 20, 3, pp. 203-212, (2021)
  • [100] Shahnawaz M., Tokuda T., Waragai M., Mendez N., Ishii R., Trenkwalder C., Et al., Development of a biochemical diagnosis of Parkinson disease by detection of α-synuclein misfolded aggregates in cerebrospinal fluid, JAMA Neurol, 74, 2, pp. 163-172, (2017)
567891011121314